CRMD
CorMedix Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05
Figures on this page computed 2026-11-08 12:41 UTC
Last close
5.66USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-05
2.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-05
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
52.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
55.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth319.8%99 of 100, above its sector
- Returns on capital40.2%96 of 100, above its sector
- Margins88.5%98 of 100, above its sector
- Price2.4x75 of 100, above its sector
- Safety2.1163 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 4- Profit on each unit of sales52.3%13.6%Ahead
Higher is better here.
- Return on the capital it usesn/a25.1%n/a
Higher is better here.
- Sales growth over five years320%0.3%Ahead
Higher is better here.
- Debt against equityn/a0.22n/a
Lower is better here.
- Gross margin88.5%74.5%Ahead
Higher is better here.
- Price against earnings2.4x13.3xAhead
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Puma Biotechnology, Inc., CRMD is behind on 0 of 4 measures.
Against Puma Biotechnology, Inc., CRMD is behind on 0 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-05
Profit on each unit of sales52.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
Sales growth over five years319.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
Gross margin88.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD
Price against earnings2.4x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001213900-26-023889
- Reported in
- USD